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The emergence of the SARS-CoV2 virus and the resulting COVID-
19 pandemic has had wide-reaching implications for day-to-day living
and medical science. In particular, cardiology as a specialty has seen
drastic changes during this period.1 On the one hand, the pandemic
has highlighted the speed with which high-quality research can be
organized.2 On the other hand, it has demonstrated significant limita-
tions in the peer-review process and medical publishing at large. The
process for journals to quickly publish high-quality, cutting-edge re-
search was found wanting in this fast-paced environment and lead to
several high profile retractions.3,4
European Heart Journal – Case Reportswas not immune to the difficul-
ties imposed by COVID-19. Unlike many other journals, the majority
of our authors are full-time clinicians. The vast majority of our editorial
and reviewing teams are also practising clinicians. Surges in clinical
workload lead to significant reductions in the effective staffing of the
journal. This was combined with significant increases in submissions
and was further complicated by a desire to provide rapid peer-review
for manuscripts at a time when the global pandemic was changing
quickly. However, throughout, European Heart Journal – Case Reports
stuck to its guiding principles.5 In particular, the need for patient ano-
nymity and consent when publishing case reports and the need to en-
sure that cases are of high quality and provide educational value.
Case reports are often considered the lowest form of evidence
within the medical literature.6 While case descriptions certainly have
significant limitations, it is in emerging diseases and techniques where
they can be of the most benefit. Early descriptions of HIV/AIDS and
the teratogenic effects of thalidomide were through case
reports.7,8COVID-19 has been no different, with case reports pro-
viding important clinical insight into a new and important disease.
The journal has received 192 submissions to date related to the
COVID-19 pandemic and effects on the cardiovascular system. In this
special issue, we present the entirety of the case reports accepted by
European Heart Journal – Case Reports during the COVID-19 pandemic
to date. They highlight that this virus, while primarily leading to re-
spiratory symptoms, has significant impacts on the heart. The effects
of this virus include potential effects on the conducting system,9
development of arrhythmias,10 coronary artery disease,11 throm-
bosis,12 and myocardial effects.13,14 In addition, there is a suggestion
that underlying cardiac disease may contribute to poor outcomes
from SARS-CoV2 infection.15 This collection is an excellent reposi-
tory demonstrating the clinical effects of COVID-19 on the cardio-
vascular system. While all of these findings would benefit from more
structured analysis, these observations provide important starting
points for further research.
European Heart Journal – Case Reports is thankful to the entire
Editorial Board and reviewing teams for their tireless work with the
journal throughout a period when their clinical activities demanded a
great deal of their time. We are also grateful to the European Society
of Cardiology for its support for the journal during the pandemic. In
particular, they provided funding for a number of COVID-19 case
reports to be published in European Heart Journal – Case Reports. This
has helped to ensure that barriers to the publication of high-quality
case reports were as low as possible.
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